Torrent Pharma Q4 FY26 Revenue Rises 42% to ₹4,197 Crore
Torrent Pharmaceuticals reported Q4 FY26 revenue of ₹4,197 crore, a 42% increase. Full-year FY26 revenue reached ₹13,980 crore, up 21%. Key growth drivers include India (Q4: ₹2,215 crore, +43%) and Brazil (Q4: ₹455 crore, +30%). The company submitted its audited financial results for the quarter and year ended March 31, 2026.
The substantial revenue growth reported for both the quarterly and annual periods, particularly the 42% increase in Q4, is a material event for investors and indicates strong business performance.
The company reported significant year-over-year revenue growth in both the fourth quarter and the full fiscal year, driven by strong performance across multiple geographies.
Torrent Pharmaceuticals Limited has submitted an investor presentation detailing the audited financial results for the quarter and year ended March 31, 2026. The presentation was sent to the BSE Limited and the National Stock Exchange of India Ltd. on May 22, 2026.
For the fourth quarter of fiscal year 2025-26, the company reported a consolidated revenue of ₹4,197 crore, marking a significant 42% increase compared to the previous year. This growth was driven by strong performance across key markets. Revenue from India surged by 43% to ₹2,215 crore, while the United States saw a 31% increase to ₹396 crore. Germany's revenue grew by 16% to ₹333 crore, and Brazil's revenue increased by 30% to ₹455 crore. The 'Others' segment also showed robust growth of 68%, contributing ₹798 crore.
For the full fiscal year 2025-26, Torrent Pharmaceuticals reported a total revenue of ₹13,980 crore, a 21% increase over the previous year. India remained the largest contributor with ₹7,645 crore in revenue, up 20%. The United States contributed ₹1,363 crore (up 24%), Germany ₹1,249 crore (up 10%), and Brazil ₹1,362 crore (up 24%). The 'Others' segment grew by 32% to ₹2,361 crore.
What to do with a filing like this
Torrent Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Torrent Pharmaceuticals Limited. Read the original for the full detail.